使用[89Zr]Zr-girentuximab PET与手术时的辐射防护考量
本研究测量了89Zr注射器和药瓶的剂量率,并在ZIRCON临床试验中评估医护人员在给药、成像和手术过程中的辐射暴露。结果显示89Zr操作和患者暴露相关的辐射水平较低,但需要适当的辐射安全指南,剂量率测量有助于制定最佳实践和现场特定方案。
要点
- 无屏蔽药瓶最大剂量率为0.334 µSv/h/MBq,66 mm铅屏蔽后最小为0.004 µSv/h/MBq。
- 成像时距患者1米处平均剂量率为3.90 µSv/h。
- 手术中废物低于本底,距患者0.8米床旁助手全身剂量率为5 µSv/h。
核心结论
- 结果表明89Zr操作和患者暴露相关的辐射暴露水平较低。
- 随着89Zr可能融入临床实践,需要适当的辐射安全指南。
- 剂量率测量有助于指导最佳实践和现场特定方案的制定。
研究设计与样本
- 实验室测量89Zr注射器和药瓶的剂量率,并在ZIRCON临床试验([89Zr]Zr-girentuximab)中测量给药、成像和手术过程中的剂量率以评估医护人员暴露。
主要发现
- 无屏蔽药瓶最大剂量率为0.334 µSv/h/MBq,66 mm铅屏蔽后最小剂量率为0.004 µSv/h/MBq。
- 受控溢出测量为0.52 µSv/h/MBq。
- 接受[89Zr]Zr-girentuximab的患者在成像时距1米处平均剂量率为3.90 µSv/h。
- 手术中废物测量低于本底水平,距患者0.8米的床旁助手全身剂量率为5 µSv/h。
- 切除的肾脏在5 cm处测量为6 µSv/h。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 89Zr is emerging as a popular positron-emitting radionuclide for imaging; however, its 909 keV gamma emission presents shielding challenges, and radiation exposure safety guidelines for healthcare professionals working with the radionuclide have not been well-established. To guide assessment of the radiation risk and necessary safety guidelines, we present laboratory dose rate measurements of 89Zr syringes and vials, and dose rates measurements made during the ZIRCON clinical trial ([89Zr]Zr-girentuximab) to evaluate healthcare provider exposure during administration, imaging, and surgical procedures. RESULTS: The maximum dose rate from a vial with no shielding was 0.334 µSv/h/MBq, and the minimum dose rate with 66 mm lead shielding was 0.004 µSv/h/MBq. The controlled spill measured 0.52 µSv/h/MBq. Dose rates 1 m from patients who received [89Zr]Zr-girentuximab had an average of 3.90 µSv/h at imaging. During surgery, waste measured below background levels, and a bed assistant 0.8 m from the patient received a 5 µSv/h whole-body dose rate. The excised kidney measured 6 µSv/h at 5 cm. CONCLUSIONS: Our results demonstrate low radiation exposure levels associated with 89Zr handling and exposure to the patient. With potential integration of 89Zr into clinical practice, appropriate radiation safety guidelines are needed. Dose rate measurements can help guide development of best practices and site-specific protocols. CLINICAL TRIAL NUMBER: not applicable for this study; ZIRCON trial number NCT03849118, registered on 19 February 2019.
引用
- Chowdhury A, Morgat C, Bailly C, et al. Radiation protection considerations with [89Zr]Zr-girentuximab PET and surgery. EJNMMI Res. 2025. PMID: 40408016. doi:10.1186/s13550-025-01247-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。